{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:44:33Z","timestamp":1785350673497,"version":"3.55.0"},"reference-count":61,"publisher":"Bioscientifica","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:p>Graves\u2019 orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves\u2019 disease. It often impairs patients\u2019 quality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the efficacy is often underwhelming and recurrence rate is high. For many years, clinicians have been searching for new methods of treatment. Rituximab (RTX) is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. It is frequently used to treat non-Hodgkin\u2019s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, or various types of vasculitis. Numerous clinical trials employing RTX in the treatment of GO have shown promising results. RTX is currently considered to be a valid second-line treatment option in patients unresponsive to previous interventions or in disease reactivation. This review summarizes the available literature on this topic, including two largest, randomized, controlled studies. Potential benefits, as well as the limitations of RTX therapy, are discussed.<\/jats:p>","DOI":"10.1530\/ec-22-0303","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T16:36:01Z","timestamp":1665506161000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":14,"title":["Rituximab in the treatment of Graves\u2019 orbitopathy: latest updates and perspectives"],"prefix":"10.1530","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-4382","authenticated-orcid":true,"given":"Jakub","family":"Supronik","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Szelachowska","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kretowski","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland"},{"name":"Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Siewko","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","unstructured":"Bahn RSGraves\u2019 ophthalmopathy. New England Journal of Medicine2010362726\u2013738. (https:\/\/doi.org\/10.1056\/NEJMra0905750)2018197410.1056\/NEJMra0905750"},{"key":"bib2","series-title":"Internal Medicine","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2169\/internalmedicine.53.1518","article-title":"Graves\u2019 ophthalmopathy: epidemiology and natural history","volume":"53","author":"Hiromatsu","year":"2014","unstructured":"Hiromatsu YEguchi HTani JKasaoka MTeshima Y. Graves\u2019 ophthalmopathy: epidemiology and natural history. Internal Medicine201453353\u2013360. (https:\/\/doi.org\/10.2169\/internalmedicine.53.1518)2458342010.2169\/internalmedicine.53.1518"},{"key":"bib3","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","unstructured":"Tanda MLPiantanida ELiparulo LVeronesi GLai ASassi LPariani NGallo DAzzolini CFerrario MPrevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center. Journal of Clinical Endocrinology and Metabolism2013981443\u20131449. (https:\/\/doi.org\/10.1210\/jc.2012-3873)10.1210\/jc.2012-3873"},{"key":"bib4","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2830","article-title":"Untreated Graves\u2019 disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance","volume":"80","author":"Villadolid","year":"1995","unstructured":"Villadolid MCYokoyama NIzumi MNishikawa TKimura HAshizawa KKiriyama TUetani MNagataki S. Untreated Graves\u2019 disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. Journal of Clinical Endocrinology and Metabolism1995802830\u20132833. (https:\/\/doi.org\/10.1210\/jcem.80.9.7673432)7673432"},{"key":"bib5","series-title":"Ophthalmic Plastic and Reconstructive Surgery","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/01.IOP.0000124675.80763.5A","article-title":"Prevalence of asymmetric exophthalmos in Graves\u2019 orbitopathy","volume":"20","author":"Soroudi","year":"2004","unstructured":"Soroudi AEGoldberg RAMcCann JD. Prevalence of asymmetric exophthalmos in Graves\u2019 orbitopathy. Ophthalmic Plastic and Reconstructive Surgery200420224\u2013225. (https:\/\/doi.org\/10.1097\/01.iop.0000124675.80763.5a)1516773110.1097\/01.IOP.0000124675.80763.5A"},{"key":"bib6","series-title":"Clinical Science","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","unstructured":"Rundle FFWilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy. Clinical Science19455177\u2013194."},{"key":"bib7","series-title":"Frontiers in Endocrinology","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena","year":"2020","unstructured":"Bartalena LPiantanida EGallo DLai ATanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Frontiers in Endocrinology202011615993. (https:\/\/doi.org\/10.3389\/fendo.2020.615993)3332940810.3389\/fendo.2020.615993"},{"key":"bib8","series-title":"Journal of Neuro-Ophthalmology","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","article-title":"The pathophysiology of thyroid eye disease","volume":"34","author":"Shan","year":"2014","unstructured":"Shan SJDouglas RS. The pathophysiology of thyroid eye disease. Journal of Neuro-Ophthalmology201434177\u2013185. (https:\/\/doi.org\/10.1097\/WNO.0000000000000132)2482110110.1097\/WNO.0000000000000132"},{"key":"bib9","series-title":"Survey of Ophthalmology","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease: emerging paradigms","volume":"55","author":"Naik","year":"2010","unstructured":"Naik VMNaik MNGoldberg RASmith TJDouglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Survey of Ophthalmology201055215\u2013226. (https:\/\/doi.org\/10.1016\/j.survophthal.2009.06.009)2038533310.1016\/j.survophthal.2009.06.009"},{"key":"bib10","series-title":"American Journal of Pathology","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","article-title":"Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves\u2019 disease","volume":"161","author":"Romagnani","year":"2002","unstructured":"Romagnani PRotondi MLazzeri ELasagni LFrancalanci MBuonamano AMilani SVitti PChiovato LTonacchera MExpression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves\u2019 disease. American Journal of Pathology2002161195\u2013206. (https:\/\/doi.org\/10.1016\/S0002-9440(1064171-5)1210710410.1016\/S0002-9440(10)64171-5"},{"key":"bib11","series-title":"Best Practice and Research: Clinical Endocrinology and Metabolism","article-title":"Graves\u2019 disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","unstructured":"Antonelli AFallahi PElia GRagusa FPaparo SRRuffilli IPatrizio AGonnella DGiusti CVirili CGraves\u2019 disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Practice and Research: Clinical Endocrinology and Metabolism202034 101388. (https:\/\/doi.org\/10.1016\/j.beem.2020.101388)32059832"},{"key":"bib12","series-title":"Hormone and Metabolic Research","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1055\/s-0032-1316352","article-title":"Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy","volume":"44","author":"Mysliwiec","year":"2012","unstructured":"Mysliwiec JPalyga IKosciuszko MKowalska AGorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy. Hormone and Metabolic Research201244957\u2013961. (https:\/\/doi.org\/10.1055\/s-0032-1316352)2275295510.1055\/s-0032-1316352"},{"key":"bib13","series-title":"Hormone and Metabolic Research","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1055\/s-0031-1271620","article-title":"Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves\u2019 disease","volume":"43","author":"Leite","year":"2011","unstructured":"Leite ACPedro ABRomaldini JH. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves\u2019 disease. Hormone and Metabolic Research201143194\u2013199. (https:\/\/doi.org\/10.1055\/s-0031-1271620)2128395310.1055\/s-0031-1271620"},{"key":"bib14","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves\u2019 disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","unstructured":"Antonelli ARotondi MFallahi PGrosso MBoni GFerrari SMRomagnani PSerio MMariani GFerrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves\u2019 disease or toxic nodular goiter. Journal of Clinical Endocrinology and Metabolism2007921485\u20131490. (https:\/\/doi.org\/10.1210\/jc.2006-1571)10.1210\/jc.2006-1571"},{"key":"bib15","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1530\/eje.1.01847","article-title":"Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis","volume":"152","author":"Antonelli","year":"2005","unstructured":"Antonelli ARotondi MFallahi PRomagnani PFerrari SMPaolicchi AFerrannini ESerio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. European Journal of Endocrinology2005152171\u2013177. (https:\/\/doi.org\/10.1530\/eje.1.01847)10.1530\/eje.1.01847"},{"key":"bib16","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","unstructured":"Bartalena LKahaly GJBaldeschi LDayan CMEckstein AMarcocci CMarino MVaidya BWiersinga WM & EUGOGO. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. European Journal of Endocrinology2021185G43\u2013G67. (https:\/\/doi.org\/10.1530\/EJE-21-0479)10.1530\/EJE-21-0479"},{"key":"bib17","series-title":"Lancet: Diabetes and Endocrinology","first-page":"287","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","unstructured":"Kahaly GJRiedl MK\u00f6nig JPitz SPonto KDiana TKampmann EKolbe EEckstein AMoeller LCMycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet: Diabetes and Endocrinology20186287\u2013298. (https:\/\/doi.org\/10.1016\/S2213-8587(1830020-2)"},{"key":"bib18","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"86","author":"Ye","year":"2017","unstructured":"Ye XBo XHu XCui HLu BShao JWang J. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy. Clinical Endocrinology201786247\u2013255. (https:\/\/doi.org\/10.1111\/cen.13170)2748404810.1111\/cen.13170"},{"key":"bib19","series-title":"Best Practice and Research: Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","article-title":"Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy","volume":"26","author":"Smith","year":"2012","unstructured":"Smith TJHeged\u00fcs LDouglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Practice and Research: Clinical Endocrinology and Metabolism201226291\u2013302. (https:\/\/doi.org\/10.1016\/j.beem.2011.10.002)2263236610.1016\/j.beem.2011.10.002"},{"key":"bib20","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","unstructured":"Krieger CCPlace RFBevilacqua CMarcus-Samuels BAbel BSSkarulis MCKahaly GJNeumann SGershengorn MC. TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis. Journal of Clinical Endocrinology and Metabolism20161012340\u20132347. (https:\/\/doi.org\/10.1210\/jc.2016-1315)2704316310.1210\/jc.2016-1315"},{"key":"bib21","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","unstructured":"Smith TJKahaly GJEzra DGFleming JCDailey RATang RAHarris GJAntonelli ASalvi MGoldberg RATeprotumumab for thyroid-associated ophthalmopathy. New England Journal of Medicine20173761748\u20131761. (https:\/\/doi.org\/10.1056\/NEJMoa1614949)2846788010.1056\/NEJMoa1614949"},{"key":"bib22","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","unstructured":"Douglas RSKahaly GJPatel ASile SThompson EHZPerdok RFleming JCFowler BTMarcocci CMarino MTeprotumumab for the treatment of active thyroid eye disease. New England Journal of Medicine2020382341\u2013352. (https:\/\/doi.org\/10.1056\/NEJMoa1910434)3197167910.1056\/NEJMoa1910434"},{"key":"bib23","series-title":"Frontiers in Endocrinology","article-title":"Insulin-like growth factor pathway and the thyroid","volume":"12","author":"Smith","year":"2021","unstructured":"Smith TJInsulin-like growth factor pathway and the thyroid. Frontiers in Endocrinology202112 653627. (https:\/\/doi.org\/10.3389\/fendo.2021.653627)"},{"key":"bib24","series-title":"American Journal of Transplantation","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","unstructured":"Pescovitz MDRituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. American Journal of Transplantation20066859\u2013866. (https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01288.x)1661132110.1111\/j.1600-6143.2006.01288.x"},{"key":"bib25","series-title":"Clinical Immunology","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.clim.2005.08.006","article-title":"The therapeutic potential of anti-CD20 \u2018what do B-cells do?\u2019","volume":"117","author":"Eisenberg","year":"2005","unstructured":"Eisenberg RLooney RJ. The therapeutic potential of anti-CD20 \u2018what do B-cells do?\u2019Clinical Immunology2005117207\u2013213. (https:\/\/doi.org\/10.1016\/j.clim.2005.08.006)1616977310.1016\/j.clim.2005.08.006"},{"key":"bib26","series-title":"International Journal of Rheumatic Diseases","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/1756-185X.12463","article-title":"Current role of rituximab in systemic lupus erythematosus","volume":"18","author":"Mok","year":"2015","unstructured":"Mok CCCurrent role of rituximab in systemic lupus erythematosus. International Journal of Rheumatic Diseases201518154\u2013163. (https:\/\/doi.org\/10.1111\/1756-185X.12463)2552265210.1111\/1756-185X.12463"},{"key":"bib27","series-title":"Clinical Rheumatology","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","article-title":"A comprehensive review of rituximab therapy in rheumatoid arthritis patients","volume":"38","author":"Tavakolpour","year":"2019","unstructured":"Tavakolpour SAlesaeidi SDarvishi MGhasemiadl MDarabi-Monadi SAkhlaghdoust MElikaei Behjati SJafarieh A. A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clinical Rheumatology2019382977\u20132994. (https:\/\/doi.org\/10.1007\/s10067-019-04699-8)3136794310.1007\/s10067-019-04699-8"},{"key":"bib28","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1530\/eje.1.02140","article-title":"The rationale for B lymphocyte depletion in Graves\u2019 disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option","volume":"154","author":"El Fassi","year":"2006","unstructured":"El Fassi DNielsen CHHasselbalch HCHeged\u00fcs L. The rationale for B lymphocyte depletion in Graves\u2019 disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology2006154623\u2013632. (https:\/\/doi.org\/10.1530\/eje.1.02140)1664500710.1530\/eje.1.02140"},{"key":"bib29","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","unstructured":"El Fassi DNielsen CHBonnema SJHasselbalch HCHeged\u00fcs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. Journal of Clinical Endocrinology and Metabolism2007921769\u20131772. (https:\/\/doi.org\/10.1210\/jc.2006-2388)1728462210.1210\/jc.2006-2388"},{"key":"bib30","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves\u2019 disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","unstructured":"Heemstra KAToes RESepers JPereira AMCorssmit EPHuizinga TWRomijn JASmit JW. Rituximab in relapsing Graves\u2019 disease, a phase II study. European Journal of Endocrinology2008159609\u2013615. (https:\/\/doi.org\/10.1530\/EJE-08-0084)1862834510.1530\/EJE-08-0084"},{"key":"bib31","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/clinem\/dgab763","article-title":"Adjuvant rituximab-exploratory trial in young people with Graves\u2019 disease","volume":"107","author":"Cheetham","year":"2022","unstructured":"Cheetham TDCole MAbinun MAllahabadia ABarratt TDavies JHDimitri PDrake AMohamed ZMurray RDAdjuvant rituximab-exploratory trial in young people with Graves\u2019 disease. Journal of Clinical Endocrinology and Metabolism2022107743\u2013754. (https:\/\/doi.org\/10.1210\/clinem\/dgab763)3468731610.1210\/clinem\/dgab763"},{"key":"bib32","series-title":"Immunology Letters","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0165-2478(03)00032-4","article-title":"B-cell depletion with rituximab-a targeted therapy for Graves\u2019 disease and autoimmune thyroiditis","volume":"88","author":"Hasselbalch","year":"2003","unstructured":"Hasselbalch HCB-cell depletion with rituximab-a targeted therapy for Graves\u2019 disease and autoimmune thyroiditis. Immunology Letters20038885\u201386. (https:\/\/doi.org\/10.1016\/s0165-2478(0300032-4)1285316710.1016\/S0165-2478(03)00032-4"},{"key":"bib33","series-title":"Journal of Endocrinological Investigation","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/BF03349216","article-title":"Immunotherapy for Graves\u2019 orbitopathy: easy enthusiasm, but let\u2019s keep trying","volume":"29","author":"Bartalena","year":"2006","unstructured":"Bartalena LTanda ML. Immunotherapy for Graves\u2019 orbitopathy: easy enthusiasm, but let\u2019s keep trying. Journal of Endocrinological Investigation2006291012\u20131016. (https:\/\/doi.org\/10.1007\/BF03349216)1725980010.1007\/BF03349216"},{"key":"bib34","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1530\/eje.1.02119","article-title":"Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression","volume":"154","author":"Salvi","year":"2006","unstructured":"Salvi MVannucchi GCampi IRossi SPSBonara PSbrozzi FGuastella CAvignone SPirola GRatiglia REfficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. European Journal of Endocrinology2006154511\u2013517. (https:\/\/doi.org\/10.1530\/eje.1.02119)1655671210.1530\/eje.1.02119"},{"key":"bib35","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1210\/jc.2013-1804","article-title":"Potential utility of rituximab for Graves\u2019 orbitopathy","volume":"98","author":"Salvi","year":"2013","unstructured":"Salvi MVannucchi GBeck-Peccoz P. Potential utility of rituximab for Graves\u2019 orbitopathy. Journal of Clinical Endocrinology and Metabolism2013984291\u20134299. (https:\/\/doi.org\/10.1210\/jc.2013-1804)2400913510.1210\/jc.2013-1804"},{"issue":"Supplement 1","key":"bib36","series-title":"Endokrynologia Polska","first-page":"1","article-title":"Pathogenesis of thyroid eye disease \u2013 does autoimmunity against the TSH receptor explain all cases?","volume":"62","author":"Wall","year":"2011","unstructured":"Wall JRLahooti H. Pathogenesis of thyroid eye disease \u2013 does autoimmunity against the TSH receptor explain all cases?Endokrynologia Polska201162 (Supplement 1) 1\u20137.22125104"},{"key":"bib37","series-title":"Current Eye Research","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/02713683.2020.1776331","article-title":"Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives","volume":"45","author":"Mishra","year":"2020","unstructured":"Mishra SMaurya VKKumar SAnkita KAKaur ASaxena SK. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Current Eye Research2020451325\u20131341. (https:\/\/doi.org\/10.1080\/02713683.2020.1776331)3256737310.1080\/02713683.2020.1776331"},{"key":"bib38","series-title":"Yonsei Medical Journal","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3349\/ymj.2013.54.4.1033","article-title":"Correlation between TSH receptor antibody assays and clinical manifestations of Graves\u2019 orbitopathy","volume":"54","author":"Jang","year":"2013","unstructured":"Jang SYShin DYLee EJChoi YJLee SYYoon JS. Correlation between TSH receptor antibody assays and clinical manifestations of Graves\u2019 orbitopathy. Yonsei Medical Journal2013541033\u20131039. (https:\/\/doi.org\/10.3349\/ymj.2013.54.4.1033)2370944210.3349\/ymj.2013.54.4.1033"},{"key":"bib39","series-title":"Endokrynologia Polska","first-page":"498","article-title":"Clinical and immunological changes in patients with active moderate-to-severe Graves\u2019 orbitopathy treated with very low-dose rituximab","volume":"68","author":"Karasek","year":"2017","unstructured":"Karasek DCibickova LKarhanova MKalitova JSchovanek JFrysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves\u2019 orbitopathy treated with very low-dose rituximab. Endokrynologia Polska201768498\u2013504. (https:\/\/doi.org\/10.5603\/EP.a2017.0040)28660988"},{"key":"bib40","series-title":"Clinical Immunology","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","article-title":"Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies","volume":"130","author":"El Fassi","year":"2009","unstructured":"El Fassi DBanga JPGilbert JAPadoa CHegedus LNielsen CH. Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology2009130252\u2013258. (https:\/\/doi.org\/10.1016\/j.clim.2008.09.007)1896430210.1016\/j.clim.2008.09.007"},{"key":"bib41","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","unstructured":"Salvi MVannucchi GCurr\u00f2 NCampi ICovelli DDazzi DSimonetta SGuastella CPignataro LAvignone SEfficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. Journal of Clinical Endocrinology and Metabolism2015100422\u2013431. (https:\/\/doi.org\/10.1210\/jc.2014-3014)2549496710.1210\/jc.2014-3014"},{"key":"bib42","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.12141","article-title":"The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy","volume":"79","author":"Mitchell","year":"2013","unstructured":"Mitchell ALGan EHMorris MJohnson KNeoh CDickinson AJPerros PPearce SHS. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy. Clinical Endocrinology201379437\u2013442. (https:\/\/doi.org\/10.1111\/cen.12141)10.1111\/cen.12141"},{"key":"bib43","series-title":"Ophthalmology","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","article-title":"Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy","volume":"117","author":"Khanna","year":"2010","unstructured":"Khanna DChong KK-LAfifiyan NFHwang CJLee DKGarneau HCGoldberg RADarwin CHSmith TJDouglas RS. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology2010117133\u2013139.e2. (https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.029)1981850710.1016\/j.ophtha.2009.05.029"},{"key":"bib44","series-title":"Clinical Endocrinology","first-page":"179","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","unstructured":"Insull EASipkova ZDavid JTurner HENorris JH. Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clinical Endocrinology201991179\u2013186. (https:\/\/doi.org\/10.1111\/cen.13970)30864162"},{"key":"bib45","series-title":"Clinical and Experimental Immunology","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2249.2010.04191.x","article-title":"Rituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions","volume":"161","author":"Vannucchi","year":"2010","unstructured":"Vannucchi GCampi IBonomi MCovelli DDazzi DCurr\u00f2 NSimonetta SBonara PPersani LGuastella CRituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology2010161436\u2013443. (https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04191.x)2052908710.1111\/j.1365-2249.2010.04191.x"},{"key":"bib46","series-title":"Hormones","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","article-title":"Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis","volume":"20","author":"Chen","year":"2021","unstructured":"Chen JChen GSun H. Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis. Hormones202120279\u2013286. (https:\/\/doi.org\/10.1007\/s42000-021-00282-6)3378371210.1007\/s42000-021-00282-6"},{"key":"bib47","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease","volume":"81","author":"Salvi","year":"1996","unstructured":"Salvi MGirasole GPedrazzoni MPasseri MGiuliani NMinelli RBraverman LERoti E. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves\u2019 disease. Journal of Clinical Endocrinology and Metabolism1996812976\u20132979. (https:\/\/doi.org\/10.1210\/jcem.81.8.8768861)8768861"},{"key":"bib48","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","unstructured":"Stan MNGarrity JACarranza Leon BGPrabin TBradley EABahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. Journal of Clinical Endocrinology and Metabolism2015100432\u2013441. (https:\/\/doi.org\/10.1210\/jc.2014-2572)2534323310.1210\/jc.2014-2572"},{"key":"bib49","series-title":"Archives of Ophthalmology","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"Small dose of rituximab for Graves\u2019 orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","unstructured":"Salvi MVannucchi GCurr\u00f2 NIntrona MRossi SBonara PCovelli DDazzi DGuastella CPignataro LSmall dose of rituximab for Graves\u2019 orbitopathy: new insights into the mechanism of action. Archives of Ophthalmology2012130122\u2013124. (https:\/\/doi.org\/10.1001\/archopthalmol.2011.1215)2223248610.1001\/archopthalmol.2011.1215"},{"key":"bib50","series-title":"European Journal of Endocrinology","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials","volume":"176","author":"Stan","year":"2017","unstructured":"Stan MNSalvi M. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves\u2019 orbitopathy \u2013 lessons from randomized control trials. European Journal of Endocrinology2017176 R101\u2013R109. (https:\/\/doi.org\/10.1530\/EJE-16-0552)27760790"},{"key":"bib51","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","unstructured":"Perros PCrombie ALMatthews JNKendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clinical Endocrinology199338367\u2013372. (https:\/\/doi.org\/10.1111\/j.1365-2265.1993.tb00516.x)831936810.1111\/j.1365-2265.1993.tb00516.x"},{"key":"bib52","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","article-title":"Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy","volume":"62","author":"Terwee","year":"2005","unstructured":"Terwee CBPrummel MFGerding MNKahaly GJDekker FWWiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves\u2019 ophthalmopathy. Clinical Endocrinology200562145\u2013155. (https:\/\/doi.org\/10.1111\/j.1365-2265.2005.02186.x)1567018910.1111\/j.1365-2265.2005.02186.x"},{"key":"bib53","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"Wiersinga","year":"2013","unstructured":"Wiersinga WMSmoking and thyroid. Clinical Endocrinology201379145\u2013151. (https:\/\/doi.org\/10.1111\/cen.12222)2358147410.1111\/cen.12222"},{"key":"bib54","series-title":"European Journal of Ophthalmology","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1120672119845224","article-title":"The effects of rituximab on Graves\u2019 orbitopathy: a retrospective study of 14 patients","volume":"30","author":"Eid","year":"2020","unstructured":"Eid LCoste-Verdier VLongueville ERibeiro ENicolescu-Catargi BKorobelnik JF. The effects of rituximab on Graves\u2019 orbitopathy: a retrospective study of 14 patients. European Journal of Ophthalmology2020301008\u20131013. (https:\/\/doi.org\/10.1177\/1120672119845224)3102559010.1177\/1120672119845224"},{"key":"bib55","series-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","article-title":"Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study","volume":"258","author":"Deltour","year":"2020","unstructured":"Deltour JBd\u2019Assigny Flamen MLadsous MGiovansili LCariou BCaron PDrui DLebranchu P. Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology20202582013\u20132021. (https:\/\/doi.org\/10.1007\/s00417-020-04651-6)3240570010.1007\/s00417-020-04651-6"},{"key":"bib56","series-title":"Ocular Immunology and Inflammation","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","article-title":"Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves\u2019 orbitopathy","volume":"30","author":"Bennedja\u00ef","year":"2022","unstructured":"Bennedja\u00ef ABouheraoua NGatfoss\u00e9 MDupasquier-Fediaevsky LErrera MHTazartes MBorderie VHennocq QDellal ARiviere STocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves\u2019 orbitopathy. Ocular Immunology and Inflammation202230500\u2013505. (https:\/\/doi.org\/10.1080\/09273948.2020.1808688)3296514810.1080\/09273948.2020.1808688"},{"key":"bib57","series-title":"Thyroid","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy","volume":"31","author":"Vannucchi","year":"2021","unstructured":"Vannucchi GCampi ICovelli DCurr\u00f2 NLazzaroni EPalomba ASoranna DZambon AFugazzola LMuller IEfficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid202131821\u2013828. (https:\/\/doi.org\/10.1089\/thy.2020.0269)3323403210.1089\/thy.2020.0269"},{"key":"bib58","series-title":"Annals of the Rheumatic Diseases","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RFEmery PBingham 3rd COKeystone ECFleischmann RMFurst DETyson NCollinson NLehane PB. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Annals of the Rheumatic Diseases2013721496\u20131502. (https:\/\/doi.org\/10.1136\/annrheumdis-2012-201956)2313624210.1136\/annrheumdis-2012-201956"},{"key":"bib59","series-title":"Expert Review of Ophthalmology","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/17469899.2017.1276444","article-title":"Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management","volume":"12","author":"Blandford","year":"2017","unstructured":"Blandford ADZhang DChundury RVPerry JD. Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management. Expert Review of Ophthalmology201712111\u2013121. (https:\/\/doi.org\/10.1080\/17469899.2017.1276444)2877576210.1080\/17469899.2017.1276444"},{"issue":"Supplement 1","key":"bib60","series-title":"European Thyroid Journal","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000510700","article-title":"Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves\u2019 orbitopathy","volume":"9","author":"Bartalena","year":"2020","unstructured":"Bartalena LWiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves\u2019 orbitopathy. European Thyroid Journal20209 (Supplement 1) 3\u201316. (https:\/\/doi.org\/10.1159\/000510700)3351108110.1159\/000510700"},{"key":"bib61","series-title":"Frontiers in Endocrinology","article-title":"Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"12","author":"Campi","year":"2021","unstructured":"Campi IVannucchi GMuller ILazzaroni ECurr\u00f2 NDainese MMontacchini BCovelli DGuastella CPignataro LTherapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves\u2019 orbitopathy. Frontiers in Endocrinology202112 790246. (https:\/\/doi.org\/10.3389\/fendo.2021.790246)35145479"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/11\/12\/EC-22-0303.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/12\/EC-22-0303.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/12\/EC-22-0303.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:50Z","timestamp":1784555150000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":61,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/ec-22-0303","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}